Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Sotorasib + TNO155|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Sotorasib||Lumakras||AMG 510|AMG510|AMG-510||KRAS G12C inhibitor 28||Lumakras (sotorasib) is small molecule inhibitor that selectively targets KRAS G12C and inhibits downstream signaling, which may lead to growth inhibition of tumors harboring KRAS G12C (PMID: 31666701). Lumakras (sotorasib) is FDA approved for use in patients with locally advanced or metastatic non-small cell lung cancer harboring KRAS G12C who have received one or more prior therapy (FDA.gov).|
|TNO155||TNO-155|TNO 155||SHP2 Inhibitor 19||TNO155 is an inhibitor of PTPN11 (SHP2), which potentially blocks SHP2 signaling, thereby inhibiting activation of the MAPK pathway and subsequent cell growth (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|